Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNTOCINON vs OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.
Increases intracellular calcium in uterine myofibrils, stimulating contractions. Binds to oxytocin receptors in myometrium and mammary glands.
Induction or augmentation of labor,Facilitation of abortion in the second trimester,Postpartum hemorrhage prevention and treatment
Induction of labor,Augmentation of labor,Facilitation of uterine contractions during the third stage of labor,Postpartum hemorrhage (off-label)
10 units (1 m L) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 m U/min (0.1-0.5 m L/min) titrated to uterine response.
IV infusion: 0.5-2 m U/min, increased by 1-2 m U/min every 30-60 min until desired uterine activity, then reduce; max 20 m U/min.
Terminal elimination half-life: 1–6 minutes (intravenous); 1–9 minutes (intramuscular). Clinically, effects dissipate rapidly after infusion cessation.
Terminal half-life: 1-6 minutes (IV); clinical effect ceases rapidly after infusion stops due to rapid clearance.
Rapidly metabolized in the liver and kidneys by oxytocinase (cysteine aminopeptidase) and other peptidases.
Metabolized primarily by oxytocinase in the liver, kidney, and placenta. Also degraded by peptidases in the gastrointestinal tract when given orally (not clinically used).
Renal: >99% as intact oxytocin; biliary/fecal: negligible (<1%).
Renal: >99% as unchanged drug; <1% hepatic metabolism and biliary excretion.
Low (~30%); primarily binds to albumin and oxytocin-specific carrier proteins (e.g., neurophysin I).
Low; approximately 30%, primarily bound to albumin.
0.2–0.3 L/kg; reflects limited distribution into extracellular fluid and minimal tissue binding.
0.2-0.3 L/kg; reflects distribution primarily in extracellular fluid.
Intramuscular: ~20–40% (due to rapid enzymatic degradation); Intravenous: 100%.
IV: 100%; IM: approximately 80-85%.
No dosage adjustment required for renal impairment; oxytocin is rapidly metabolized and renally excreted, but no specific GFR-based guidelines exist.
No specific GFR-based dose adjustment for oxytocin. Use with caution in severe renal impairment due to fluid overload risk from dextrose 5%.
No dosage adjustment required for hepatic impairment; oxytocin is metabolized primarily by the liver, but no Child-Pugh based modifications have been established.
No specific Child-Pugh-based adjustment. Use with caution in severe hepatic impairment.
Not indicated for pediatric use; safety and efficacy in children have not been established.
Not indicated in pediatric patients. Use in adolescents for labor induction similar to adult dosing.
Use with caution in elderly patients due to potential for uterine hyperstimulation and adverse cardiovascular effects; no specific dosage adjustments recommended.
Not typically used in geriatric population. If used, start at low end of dosing range and monitor for fluid overload and cardiovascular effects.
NOT FOR ELECTIVE INDUCTION OF LABOR AT TERM DUE TO RISK OF UTERINE HYPERSTIMULATION, UTERINE RUPTURE, AND FETAL DISTRESS. SHOULD ONLY BE USED UNDER CONTINUOUS MEDICAL SUPERVISION WITH FETAL AND UTERINE MONITORING.
Oxytocin should be administered only by intravenous infusion with careful monitoring. Severe adverse effects, including uterine rupture, water intoxication, and fetal distress, can occur. It is not intended for prolonged use.
Uterine hyperstimulation and tetany,Uterine rupture, especially in grand multipara or with prior cesarean,Water intoxication and hyponatremia due to antidiuretic effect (high doses),Fetal bradycardia, hypoxia, and neonatal jaundice,Hypotension and tachycardia with rapid IV administration
May cause uterine hyperstimulation leading to fetal distress, uterine rupture, or maternal death. Risk of water intoxication with high doses or prolonged infusion. Monitor maternal vital signs, uterine activity, and fetal heart rate continuously.
Hypersensitivity to oxytocin or any component,Cephalopelvic disproportion,Fetal distress where delivery is not imminent,Prolapsed umbilical cord,Placenta previa,Vasa previa,Contraindicated for elective induction in term pregnancies
Hypersensitivity to oxytocin,Cephalopelvic disproportion,Fetal distress where vaginal delivery is not imminent,Uterine scarring (e.g., prior cesarean section),Placenta previa
No food interactions are known. However, because oxytocin can cause water retention, advise moderate sodium intake to reduce risk of hyponatremia. No specific dietary restrictions.
No known food interactions. Maintain adequate hydration as per clinical status.
Syntocinon (oxytocin) is not associated with teratogenic effects when used at standard doses for labor induction. However, prolonged high-dose exposure may cause fetal hypoxia, bradycardia, and neonatal hyperbilirubinemia. No trimester-specific malformation risk is established; uterine hyperstimulation risk is greatest during second and third trimester use.
Oxytocin is not associated with structural teratogenicity. In the first trimester, no increased risk of congenital anomalies has been reported. In the second and third trimesters, exogenous oxytocin is used therapeutically for induction/augmentation of labor and may cause uterine hyperstimulation, leading to fetal distress, hypoxia, or preterm birth if not properly monitored.
Oxytocin is endogenous in breast milk; exogenous administration does not significantly increase milk levels. M/P ratio not clinically relevant due to rapid metabolism. Considered compatible with breastfeeding.
Exogenous oxytocin is rapidly metabolized in maternal plasma and gastrointestinal tract; it is not orally bioavailable to the infant. Endogenous oxytocin is essential for milk ejection. No M/P ratio is established; however, systemic levels from exogenous administration are negligible in breast milk. Considered compatible with breastfeeding.
No standard dose adjustment required due to pregnancy-induced pharmacokinetic changes. However, uterine sensitivity to oxytocin increases with gestational age; lower starting doses may be used near term to avoid hyperstimulation.
No pharmacokinetic-based dose adjustment is needed as oxytocin is administered intravenously with dose titration to effect. Pregnancy does not significantly alter its metabolism or clearance. Dosing is based on uterine response and fetal status, not altered due to pregnancy-related PK changes.
Syntocinon (oxytocin) is used for induction or augmentation of labor. Administer via controlled IV infusion using an infusion pump. Start at 0.5-2 m U/min and titrate every 30-60 min to achieve adequate contractions (3-5 per 10 min). Monitor for uterine hyperstimulation, fetal distress, or water intoxication (antidiuretic effect). Have magnesium sulfate, terbutaline, or other tocolytics available for hyperstimulation. Do not use if contraindicated (e.g., cephalopelvic disproportion, fetal distress, placenta previa).
Administer as a continuous IV infusion with strict monitoring of uterine activity and fetal heart rate. Use an infusion pump to avoid bolus administration. Hypotension and tachycardia may occur with rapid infusion; slow rate if hyperstimulation occurs. Have magnesium sulfate available for tocolysis if needed. Do not use for elective induction before 39 weeks gestation.
Syntocinon is given intravenously to start or strengthen labor contractions.,You will be closely monitored with an electronic fetal monitor.,Report any excessively frequent or prolonged contractions or severe pain immediately.,It may increase the risk of postpartum hemorrhage; staff is prepared to manage it.,Tell your healthcare provider about any history of heart disease or high blood pressure.
This medication is given to start or strengthen labor contractions.,You will be monitored closely for your baby's heart rate and your contractions.,Report any contractions that are too frequent or prolonged, or if you feel severe pain.,Tell your nurse immediately if you have difficulty breathing or signs of allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNTOCINON vs OXYTOCIN 10 USP UNITS IN DEXTROSE 5%, answered by our medical review team.
SYNTOCINON is a Oxytocic that works by Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.. OXYTOCIN 10 USP UNITS IN DEXTROSE 5% is a Oxytocic that works by Increases intracellular calcium in uterine myofibrils, stimulating contractions. Binds to oxytocin receptors in myometrium and mammary glands.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNTOCINON and OXYTOCIN 10 USP UNITS IN DEXTROSE 5% depend on the specific clinical indication. These are both Oxytocic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNTOCINON is: 10 units (1 m L) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 m U/min (0.1-0.5 m L/min) titrated to uterine response.. The standard adult dose of OXYTOCIN 10 USP UNITS IN DEXTROSE 5% is: IV infusion: 0.5-2 m U/min, increased by 1-2 m U/min every 30-60 min until desired uterine activity, then reduce; max 20 m U/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNTOCINON and OXYTOCIN 10 USP UNITS IN DEXTROSE 5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNTOCINON is classified as Category C. Syntocinon (oxytocin) is not associated with teratogenic effects when used at standard doses for labor induction. However, prolonged high-dose exposure may cause fetal hypoxia, bra. OXYTOCIN 10 USP UNITS IN DEXTROSE 5% is classified as Category C. Oxytocin is not associated with structural teratogenicity. In the first trimester, no increased risk of congenital anomalies has been reported. In the second and third trimesters, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.